Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 104Fallopian Tube Neoplasms 47Carcinoma, Ovarian Epithelial 27Neoplasms 12Breast Neoplasms 7Neoplasm Metastasis 5Recurrence 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Peritoneal Neoplasms 3Ovarian Cancer Recurrent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Multiple Myeloma 2Lung Neoplasms 2Disease Progression 2Colorectal Neoplasms 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Doxorubicin 2niraparib 1copanlisib 1Standard of Care 1Saline Solution 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Lidocaine 1Gemcitabine 1Conservative Treatment 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Disease Progression × liposomal doxorubicin × Gynecologic × Clear all
NCT03804866 2019-01-15

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

AGC Biologics S.p.A.

Phase 2 Completed
14 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT01358071 2018-09-27

NGR018

AGC Biologics S.p.A.

Phase 2 Completed
119 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡